Webinar: Meeting New Challenges and Opportunities at the Frontier of Thrombosis Research
Date: Friday, 18 December 2020
Time: 12:30 pm – 2:00 pm EST
Register here: (Update: Registration now closed)
- Dr. Lana Castellucci, Assistant Professor, Department of Medicine, uOttawa Faculty of Medicine
- Dr. Lisa Duffett, Assistant Professor, Department of Medicine, uOttawa Faculty of Medicine
- Dr. Deborah Siegal, Associate Professor, Department of Medicine, uOttawa Faculty of Medicine
Moderator: Dr. Philip Wells, Full Professor and Chair/Chief, Department of Medicine at the uOttawa Faculty of Medicine and The Ottawa Hospital
As the end of this webinar, participants will be able to:
- Outline why patient and caregiver engagement is needed in research.
- Describe how patients and caregivers can contribute to research, citing specific examples
- Describe the importance of anticoagulant related bleeding and areas of clinical uncertainty regarding anticoagulant management
- Describe coagulation changes in COVID-19 and clinical manifestations of COVID-19 Coagulopathy
- Present thromboprophylaxis strategies for Patients with COVID-19
Lana Castellucci, MD, FRCPC, MSc
Dr. Lana Castellucci is an Assistant Professor in the Faculty of Medicine at the University of Ottawa, and a Scientist at The Ottawa Hospital Research Institute. She is a member of the ISTH World Thrombosis Day Steering Committee. She sits on the Board of Directors of Thrombosis Canada, a national organization promoting patient education and improved outcomes for patients with venous thrombosis. She is an active member of the CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network, and she is a recipient of the University of Ottawa Tier 2 Research Chair in Thrombosis and Anticoagulation Safety and the Heart and Stroke Foundation of Canada National New Investigator Award.
Dr. Castellucci’s clinical and research interests are focused on the prevention, diagnosis and management of anticoagulant-related bleeding in venous and arterial thromboembolism. She is the Principal Investigator of a peer-reviewed international clinical trial (funded by the Canadian Institutes of Health Research) Comparison of Bleeding Risk between Rivaroxaban and Apixaban (COBRRA) in patients with acute venous thromboembolism.
Lisa Duffett, MD, FRCPC
Dr. Duffett is a Hematologist with The Ottawa Hospital with a subspecialty in Thrombosis. Dr. Duffett is an Associate Scientist with the Ottawa Hospital Research Institute and Assistant Professor with the University of Ottawa. Dr. Duffett professional interest is in patient and public engagement in research. Dr. Duffett is a co-lead and creator of the Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Patient Partner Platform. This program includes the recruitment, training and mentoring of patients (and/or caregivers) who collaborate on major clinical trials conducted as part of the research network. Dr. Duffett is an establishing leader in patient engagement and have given invited national presentations, author of an invited review paper and is principal investor (1) and co-investigator (7) on external peer-reviewed grants with inclusion of patient engagement.
Deborah Siegal, MD, MSc, FRCPC
Dr. Deborah Siegal is an Associate Professor of Medicine at the University of Ottawa and Associate Scientist at the Ottawa Hospital Research Institute.
Dr. Siegal graduated from Queen’s University School of Medicine in 2009 and completed Internal Medicine and Hematology training at McMaster University. She holds Master of Science degrees in Pharmacology (University of Toronto) and Health Research Methodology (McMaster University).
Dr. Siegal’s primary research interests include (i) improving patient outcomes after anticoagulant-related bleeding, (ii) management of anticoagulants in patients who have acute bleeding complications or require urgent surgery, (iii) understanding the factors that influence patient and physician decision-making after anticoagulant-related bleeding, and (iv) reducing red blood cell transfusion by minimizing iatrogenic blood loss for laboratory testing.
Dr. Siegal has expertise in the design and conduct of pragmatic cluster randomized trials, individual patient randomized trials, mixed-methods studies, observational studies and meta-analyses. She has received peer-reviewed grant support as principal investigator from the Canadian Institutes of Health Research, the American Society of Hematology, CanVECTOR/Heart and Stroke Foundation of Canada, Ontario AFP Innovation Fund, and Hamilton Health Sciences Foundation. She has published over 75 peer-reviewed articles including several in high-impact journals such as The New England Journal of Medicine, Circulation, Blood, and Journal of Thrombosis and Haemostasis.
Philip Stephen Wells, MD, FRCP(C), MSc
Dr. Wells is the Chief/Chair of the Department of Medicine at The Ottawa Hospital and the University of Ottawa. The Department consists of 17 Divisions, almost 500 physicians and over 200 post graduate trainees. He received his medical school education and specialty training in Internal Medicine at the University of Ottawa. He then studied Hematology and completed a Masters in Clinical Epidemiology at McMaster University, concentrating on the special problems of venous thrombosis (blood clots in the veins). He came on Faculty at UO in 1994 and established the Thrombosis Treatment and Assessment Unit at The Ottawa Hospital, now the largest thrombosis clinical practice and clinical research unit in the world. He is perhaps best known for pioneering the concept of clinical prediction rules to assist in the diagnosis of patients with suspected deep vein thrombosis and/or pulmonary embolism. For each of these diseases he embodied these prediction rules in valuable algorithms now known as the “Wells Model for DVT” and the “Wells Model for PE”. They are currently used world-wide in the diagnostic process for these illnesses and are incorporated into many National and Organizational guidelines. His current interests are in Cancer Associated Thrombosis and in promoting the use of AI to improve or develop clinical predictive analytics. He is currently a University of Ottawa Faculty of Medicine Distinguished Research Chair in Translational and AI Research in Venous Thrombosis.
Dr. Wells has received over 30 million dollars in peer reviewed research funding and has over 365 publications in a wide array of prestigious journals such as the New England Journal of Medicine, JAMA, Circulation, Blood, Nature Genetics and Lancet. His work has been acknowledged through a Canada Research Chair (2001 to 2011), The Ottawa Hospital J. David Grimes Career Achievement Award in 2012, a University of Ottawa Lifetime Achievement Award in 2014, and a University of Ottawa Research Chair in 2019.
Follow us on Twitter @uOttawaIGHOMed, Instagram @igho_bism, or visit us at IGHO website for the latest!
IGHO: We build bridges locally and around the world.
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the University of Ottawa’s Office of Continuing Professional Development. You may claim a maximum of 1.5 hours (credits are automatically calculated).
This one-credit-per-hour Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by the University of Ottawa’s Office of Continuing Professional Development for up to 1.5 Mainpro+ credits.